T1	Participants 44 102	Patients with pulmonary embolism or deep venous thrombosis
T2	Participants 203 245	patients with an enhanced risk of bleeding
T3	Participants 528 573	patients receiving continuous heparin therapy
T4	Participants 1425 1462	patients with a high risk of bleeding
